The Ability of Polymorphisms in DNA Repair Enzymes to Predict Clinical Outcome in Colorectal Cancer Patients

摘要: Background: Genomic polymorphisms of DNA repair enzymes/excision cross complementation group 1 (ERCC1), excision 2 (ERCC2), and X-ray (XRCC1) correlate with survival therapeutic responses in colorectal cancer (CRC) patients. Therefore, the present study examined frequency ERCC1 C118T, ERCC2 Lys751Gln, XRCC1 Arg399Gln their prognostic predictive values CRC Method: In this retrospective study, a total 143 patients were evaluated for these by PCR-RFLP. Results: The majority showed heterozygous C/T (56%) compared to wild type C/C (29%) variant T/T (15%) genotypes C118T polymorphism. Lys751Gln polymorphism A/A (44%), A/C (40%), (16%). was 48% (wild G/G), 42% (heterozygous G/A), 10% (variant A/A). relapse-free (RFS) significantly decreased 118 genotype subgroups advanced stage colon cancer; however, correlated reduced overall (OS) treated combined drug 5-FU/Oxaliplatin. Taken together, 5-FU/Oxaliplatin, led unfavorable clinical outcomes. However, did not show any significant association prognosis. Additionally, on analyzing effect polymorphisms, OS both (ERCC1: ERCC2: A/A) found. Furthermore, subgroup RFS Conclusion: relationship prognosis treatment response reflects vital role molecules as markers CRC. evaluation might identify high risk poor